Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 7
Submit an article Journal homepage
242
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Association of Genetic Variation in Pharmacodynamic Factors with Methadone Dose Required for Effective Treatment of Opioid Addiction

Orna Levran1 Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, USACorrespondence[email protected]
View further author information
,
Einat Peles2 Dr Miriam & Sheldon G Adelson Clinic for Drug Abuse Treatment & Research, Elias Sourasky Medical Center, Tel Aviv, IsraelView further author information
,
Matthew Randesi1 Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, USAView further author information
,
Xu Shu3 Department of Biostatistics, University of Michigan, Ann Arbor, MI, USAView further author information
,
Jurg Ott4 Institute of Psychology CAS, Beijing, China;5 Laboratory of Statistical Genetics, The Rockefeller University, New York, NY, USAView further author information
,
Pei-Hong Shen6 Laboratory of Neurogenetics, National Institute on Alcohol Abuse & Alcoholism, Bethesda, MD, USAView further author information
,
Miriam Adelson2 Dr Miriam & Sheldon G Adelson Clinic for Drug Abuse Treatment & Research, Elias Sourasky Medical Center, Tel Aviv, IsraelView further author information
&
Mary Jeanne Kreek1 Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, USAView further author information
 show all
Pages 755-768 | Published online: 08 May 2013

References

  • Kreek MJ , BorgL, DucatE, RayB. Pharmacotherapy in the treatment of addiction: methadone. J. Addict. Dis.29(2) , 200–216 (2010).
  • Wang L , McleodHL, WeinshilboumRM. Genomics and drug response. N. Engl. J. Med.364(12) , 1144–1153 (2011).
  • Gorman AL , ElliottKJ, InturrisiCE. The D- and L-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci. Lett.223(1) , 5–8 (1997).
  • Fredheim OM , MoksnesK, BorchgrevinkPC, KaasaS, DaleO. Clinical pharmacology of methadone for pain. Acta Anaesthesiol. Scand.52(7) , 879–889 (2008).
  • Adelson M , PelesE, BodnerG, KreekMJ. Correlation between high methadone doses and methadone serum levels in methadone maintenance treatment (MMT) patients. J. Addict. Dis.26(1) , 15–26 (2007).
  • Kreek MJ . Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann. NY Acad. Sci.909 , 186–216 (2000).
  • Plomin R , HaworthCM, DavisOS. Common disorders are quantitative traits. Nat. Rev. Genet.10(12) , 872–878 (2009).
  • Bohn LM , LefkowitzRJ, GainetdinovRR, PeppelK, CaronMG, LinFT. Enhanced morphine analgesia in mice lacking β-arrestin 2. Science286(5449) , 2495–2498 (1999).
  • Gainetdinov RR , PremontRT, BohnLM, LefkowitzRJ, CaronMG. Desensitization of G protein-coupled receptors and neuronal functions. Annu. Rev. Neurosci.27 , 107–144 (2004).
  • Shukla AK , XiaoK, LefkowitzRJ. Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem. Sci.36(9) , 457–469 (2011).
  • Sinha R . Stress and addiction: a dynamic interplay of genes, environment, and drug intake. Biol. Psychiatry66(2) , 100–101 (2009).
  • Le Merrer J , BeckerJA, BefortK, KiefferBL. Reward processing by the opioid system in the brain. Physiol. Rev.89(4) , 1379–1412 (2009).
  • Di Chiara G , BassareoV, FenuS et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 47(Suppl. 1) , 227–241 (2004).
  • Di Chiara G , ImperatoA. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl Acad. Sci. USA85(14) , 5274–5278 (1988).
  • Hoenicka J , Quinones-LombranaA, Espana-SerranoL et al. The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine. Biol. Psychiatry 67(1) , 3–11 (2010).
  • Garrido E , PalomoT, PonceG, Garcia-ConsuegraI, Jimenez-ArrieroMA, HoenickaJ. The ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and shows a differential response of Ala239Thr to apomorphine. Neurotox. Res.20(1) , 32–39 (2011).
  • Callahan RJ , AuJD, PaulM, LiuC, YostCS. Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in Xenopus oocytes: stereospecific and subunit effects. Anesth. Analg.98(3) , 653–659 (2004).
  • Levran O , LondonoD, O‘HaraK et al. Heroin addiction in African Americans: a hypothesis-driven association study. Genes Brain Behav. 8(5) , 531–540 (2009).
  • Autry AE , MonteggiaLM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev.64(2) , 238–258 (2012).
  • Cowansage KK , LedouxJE, MonfilsMH. Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. Curr. Mol. Pharmacol.3(1) , 12–29 (2010).
  • Nestler EJ , BarrotM, DileoneRJ, EischAJ, GoldSJ, MonteggiaLM. Neurobiology of depression. Neuron34(1) , 13–25 (2002).
  • Koo JW , Mazei-RobisonMS, ChaudhuryD et al. BDNF is a negative modulator of morphine action. Science 338(6103) , 124–128 (2012).
  • Levran O , PelesE, HamonS et al. Nerve growth factor β polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment. Pharmacogenomics J. 12(4) , 319–327 (2012).
  • de Cid R , FonsecaF, GratacosM et al. BDNF variability in opioid addicts and response to methadone treatment: preliminary findings. Genes Brain Behav. 7(5) , 515–522 (2008).
  • Oneda B , CrettolS, BochudM et al. β-arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J. 11(4) , 258–266 (2011).
  • Hung CC , ChiouMH, HuangBH et al. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics 12(11) , 1525–1533 (2011).
  • Crettol S , BessonJ, Croquette-KrokarM et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(7) , 1722–1727 (2008).
  • Barratt DT , CollerJK, SomogyiAA. Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. Am. J. Med. Genet. B. Neuropsychiatr. Genet.141(4) , 323–331 (2006).
  • Lawford BR , YoungRM, NobleEP et al. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am. J. Med. Genet. 96(5) , 592–598 (2000).
  • Doehring A , HentigN, GraffJ et al. Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet. Genomics 19(6) , 407–414 (2009).
  • Levran O , O‘HaraK, PelesE et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum. Mol. Genet.17(14) , 2219–2227 (2008).
  • Levran O , PelesE, HamonS, RandesiM, AdelsonM, KreekMJ. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict. Biol. doi:10.1111/j.1369-1600.2011.00349.x (2011) (Epub ahead of print).
  • Hodgkinson CA , YuanQ, XuK et al. Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol. 43(5) , 505–515 (2008).
  • Levran O , LondonoD, O‘HaraK et al. Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav. 7(7) , 720–729 (2008).
  • Enoch MA , ShenPH, XuK, HodgkinsonC, GoldmanD. Using ancestry-informative markers to define populations and detect population stratification. J. Psychopharmacol.20(4 Suppl.) , 19–26 (2006).
  • Attar MA , SalemJC, PurselHS, SantyLC. CNK3 and IPCEF1 produce a single protein that is required for HGF dependent Arf6 activation and migration. Exp. Cell Res.318(3) , 228–237 (2012).
  • Liu QR , WaltherD, DrgonT et al. Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson‘s disease. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 134B(1) , 93–103 (2005).
  • Rozen S , SkaletskyH. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol.132 , 365–386 (2000).
  • Purcell S , NealeB, Todd-BrownK et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3) , 559–575 (2007).
  • Barrett JC , FryB, MallerJ, DalyMJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics21(2) , 263–265 (2005).
  • Ducci F , RoyA, ShenPH et al. Association of substance use disorders with childhood trauma but not African genetic heritage in an African–American cohort. Am. J. Psychiatry 166(9) , 1031–1040 (2009).
  • Hout MC , PapeshMH, GoldingerSD. Multidimensional scaling. Wiley Interdiscip. Rev. Cogn. Sci.4(1) , 93–103 (2013).
  • Metz CE . Basic principles of ROC analysis. Semin. Nucl. Med.8(4) , 283–298 (1978).
  • Chen Z , SimmonsMS, PerryRT, WienerHW, HarrellLE, GoRC. Genetic association of neurotrophic tyrosine kinase receptor type 2 (NTRK2) with Alzheimer‘s disease. Am. J. Med. Genet. B. Neuropsychiatr. Genet.147(3) , 363–369 (2008).
  • Behar DM , YunusbayevB, MetspaluM et al. The genome-wide structure of the Jewish people. Nature 466(7303) , 238–242 (2010).
  • Atzmon G , HaoL, Pe‘erI et al. Abraham‘s children in the genome era: major Jewish diaspora populations comprise distinct genetic clusters with shared Middle Eastern Ancestry. Am. J. Hum. Genet. 86(6) , 850–859 (2010).
  • Tian C , KosoyR, NassirR et al. European population genetic substructure: further definition of ancestry informative markers for distinguishing among diverse European ethnic groups. Mol. Med. 15(11–12) , 371–383 (2009).
  • Modarresi F , FaghihiMA, Lopez-ToledanoMA et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat. Biotechnol. 30(5) , 453–459 (2012).
  • Okada T , HashimotoR, NumakawaT et al. A complex polymorphic region in the brain-derived neurotrophic factor (BDNF) gene confers susceptibility to bipolar disorder and affects transcriptional activity. Mol. Psychiatry 11(7) , 695–703 (2006).
  • Soliman F , GlattCE, BathKG et al. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science 327(5967) , 863–866 (2010).
  • Egan MF , KojimaM, CallicottJH et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2) , 257–269 (2003).
  • Su N , ZhangL, FeiF et al. The brain-derived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response. Brain Res. 1415 , 119–126 (2011).
  • Zhang K , YangC, XuY et al. Genetic association of the interaction between the BDNF and GSK3B genes and major depressive disorder in a Chinese population. J. Neural. Transm. 117(3) , 393–401 (2010).
  • Cheng CY , HongCJ, YuYW, ChenTJ, WuHC, TsaiSJ. Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res. Mol. Brain Res.140(1–2) , 86–90 (2005).
  • Uhl GR , LiuQR, WaltherD, HessJ, NaimanD. Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. Am. J. Hum. Genet.69(6) , 1290–1300 (2001).
  • Liu L , ForoudT, XueiX et al. Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder. Psychiatr. Genet. 18(6) , 267–274 (2008).
  • Neves-Pereira M , MundoE, MugliaP, KingN, MacciardiF, KennedyJL. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am. J. Hum. Genet.71(3) , 651–655 (2002).
  • Sklar P , GabrielSB, McInnisMG et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Mol. Psychiatry 7(6) , 579–593 (2002).
  • Meng X , KouC, ShiJ, YuY, HuangY. Susceptibility genes, social environmental risk factors and their interactions in internalizing disorders among mainland Chinese undergraduates. J. Affect. Disord.132(1–2) , 254–259 (2011).
  • Pae CU , ChiesaA, PorcelliS et al. Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Neuropsychobiology 65(1) , 1–11 (2012).
  • Xie B , WangB, SuoP et al. Genetic association between BDNF gene polymorphisms and phobic disorders: a case–control study among mainland Han Chinese. J. Affect. Disord. 132(1–2) , 239–242 (2011).
  • Kocabas NA , AntonijevicI, FaghelC et al. Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int. Clin. Psychopharmacol. 26(1) , 1–10 (2011).
  • Gratacos M , SoriaV, UrretavizcayaM et al. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J. 8(2) , 101–112 (2008).
  • Real E , GratacosM, SoriaV et al. A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder. Biol. Psychiatry 66(7) , 674–680 (2009).
  • Mercader JM , RibasesM, GratacosM et al. Altered brain-derived neurotrophic factor blood levels and gene variability are associated with anorexia and bulimia. Genes Brain Behav. 6(8) , 706–716 (2007).
  • Beuten J , MaJZ, PayneTJ et al. Significant association of BDNF haplotypes in European–American male smokers but not in European–American female or African–American smokers. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 139B(1) , 73–80 (2005).
  • Petryshen TL , SabetiPC, AldingerKA et al. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol. Psychiatry 15(8) , 810–815 (2010).
  • Beuten J , MaJZ, PayneTJ et al. Association of specific haplotypes of neurotrophic tyrosine kinase receptor 2 gene (NTRK2) with vulnerability to nicotine dependence in African–Americans and European–Americans. Biol. Psychiatry 61(1) , 48–55 (2007).
  • Alonso P , GratacosM, MenchonJM et al. Extensive genotyping of the BDNF and NTRK2 genes define protective haplotypes against obsessive-compulsive disorder. Biol. Psychiatry 63(6) , 619–628 (2008).
  • Perroud N , AitchisonKJ, UherR et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology 34(12) , 2517–2528 (2009).
  • Murphy TM , RyanM, FosterT et al. Risk and protective genetic variants in suicidal behaviour: association with SLC1A2, SLC1A3, 5-HTR1B and NTRK2 polymorphisms. Behav. Brain Funct. 7 , 22 (2011).
  • Xu K , AndersonTR, NeyerKM et al. Nucleotide sequence variation within the human tyrosine kinase B neurotrophin receptor gene: association with antisocial alcohol dependence. Pharmacogenomics J. 7(6) , 368–379 (2007).
  • Correia CT , CoutinhoAM, SequeiraAF et al. Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism. Genes Brain Behav. 9(7) , 841–848 (2010).
  • Dong C , WongML, LicinioJ. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican–Americans. Mol. Psychiatry14(12) , 1105–1118 (2009).
  • Usiello A , BaikJH, Rouge-PontF et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408(6809) , 199–203 (2000).
  • Bertolino A , FazioL, CaforioG et al. Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain 132(Pt 2) , 417–425 (2009).
  • Zhang Y , BertolinoA, FazioL et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc. Natl Acad. Sci. USA 104(51) , 20552–20557 (2007).
  • Moyer RA , WangD, PappAC et al. Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse. Neuropsychopharmacology 36(4) , 753–762 (2011).
  • Neville MJ , JohnstoneEC, WaltonRT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat.23(6) , 540–545 (2004).
  • Gelernter J , YuY, WeissR et al. Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Hum. Mol. Genet. 15(24) , 3498–3507 (2006).
  • Yang BZ , KranzlerHR, ZhaoH, GruenJR, LuoX, GelernterJ. Association of haplotypic variants in DRD2, ANKK1, TTC12 and NCAM1 to alcohol dependence in independent case–control and family samples. Hum. Mol. Genet.16(23) , 2844–2853 (2007).
  • Noble EP . The D2 dopamine receptor gene: a review of association studies in alcoholism. Behav. Genet.23(2) , 119–129 (1993).
  • Chen D , LiuF, ShangQ, SongX, MiaoX, WangZ. Association between polymorphisms of DRD2 and DRD4 and opioid dependence: evidence from the current studies. Am. J. Med. Genet. B. Neuropsychiatr. Genet.156B(6) , 661–670 (2011).
  • New AS , Perez-RodriguezMM, RipollL et al. Exploratory association study of genetic variation in OPRM1 gene and interpersonal dysfunction in a personality disorder enriched sample. Neuropsychopharmacology 36 , S324–S449 (2011).
  • Shabalina SA , ZaykinDV, GrisP et al. Expansion of the human µ-opioid receptor gene architecture: novel functional variants. Hum. Mol. Genet. 18(6) , 1037–1051 (2009).
  • Pasternak GW . Molecular insights into µ opioid pharmacology: from the clinic to the bench. Clin. J. Pain26(Suppl. 10) , S3–S9 (2010).
  • Pan L , XuJ, YuR, XuMM, PanYX, PasternakGW. Identification and characterization of six new alternatively spliced variants of the human µ opioid receptor gene. Oprm. Neuroscience133(1) , 209–220 (2005).
  • Kreek MJ , BartG, LillyC, LaforgeKS, NielsenDA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol. Rev.57(1) , 1–26 (2005).
  • Bond C , LaForgeKS, TianM et al. Single-nucleotide polymorphism in the human µ opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95(16) , 9608–9613 (1998).
  • Mague SD , BlendyJA. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend.108(3) , 172–182 (2010).
  • Levran O , YuferovV, KreekMJ. The genetics of the opioid system and specific drug addictions. Hum. Genet.131(6) , 823–842 (2012).
  • Barratt DT , CollerJK, HallinanR et al. ABCB1 haplotype and OPRM1 118A>G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics Pers. Med.5 , 53–62 (2012).
  • McGough JJ , FaraoneSV. Estimating the size of treatment effects: moving beyond p values. Psychiatry (Edgmont.)6(10) , 21–29 (2009).
  • Siegel B , VukicevicJ, SpitzerRL. Using signal detection methodology to revise DSM-III-R: re-analysis of the DSM-III-R national field trials for autistic disorder. J. Psychiatr. Res.24(4) , 293–311 (1990).
  • Faraone SV , BiedermanJ, SpencerT et al. Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis. Behav. Brain Funct. 1 , 16 (2005).
  • Lenzini PA , GriceGR, MilliganPE et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J. Thromb. Haemost. 6(10) , 1655–1662 (2008).
  • Bruehl S , ApkarianAV, BallantyneJC et al. Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. J. Pain 14(2) , 103–113 (2013).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.